Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ITCINASDAQ:MDGLNASDAQ:NBRVNASDAQ:TBPHNASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITCIIntra-Cellular Therapies$131.87$131.87$66.26▼$131.98$14.05B0.691.52 million shsN/AMDGLMadrigal Pharmaceuticals$295.16-2.5%$292.49$200.63▼$377.46$6.55B-1.08357,567 shs118,854 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shs395 shsTBPHTheravance Biopharma$10.92-1.0%$10.03$7.44▼$11.82$546.25M-0.09267,941 shs109,761 shsTGTXTG Therapeutics$35.40-1.7%$37.03$16.65▼$46.48$5.65B1.942.91 million shs1.02 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITCIIntra-Cellular Therapies0.00%0.00%0.00%0.00%+92.54%MDGLMadrigal Pharmaceuticals+0.63%+6.94%+9.37%-6.59%+8.02%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%+4,900.00%TBPHTheravance Biopharma-1.69%+4.35%+19.24%+22.28%+30.07%TGTXTG Therapeutics-1.99%-1.56%+1.90%-4.66%+102.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationITCIIntra-Cellular Therapies0.9231 of 5 stars1.10.00.04.50.01.70.6MDGLMadrigal Pharmaceuticals3.9647 of 5 stars3.40.00.04.61.63.30.6NBRVNabriva TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATBPHTheravance Biopharma2.0212 of 5 stars3.30.00.00.02.62.50.6TGTXTG Therapeutics3.7388 of 5 stars2.41.00.03.52.22.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceITCIIntra-Cellular Therapies 2.17Hold$109.70-16.81% DownsideMDGLMadrigal Pharmaceuticals 2.89Moderate Buy$420.6342.51% UpsideNBRVNabriva Therapeutics 0.00N/AN/AN/ATBPHTheravance Biopharma 2.67Moderate Buy$16.6052.00% UpsideTGTXTG Therapeutics 2.80Moderate Buy$40.8015.27% UpsideCurrent Analyst Ratings BreakdownLatest MDGL, TBPH, NBRV, TGTX, and ITCI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025TBPHTheravance BiopharmaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$24.00 ➝ $25.006/17/2025TBPHTheravance BiopharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$24.005/2/2025MDGLMadrigal PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$441.00 ➝ $458.005/2/2025MDGLMadrigal PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$422.00 ➝ $460.005/2/2025MDGLMadrigal PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$394.00 ➝ $420.004/24/2025MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$443.00 ➝ $443.004/2/2025ITCIIntra-Cellular TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$132.00 ➝ $132.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44MDGLMadrigal Pharmaceuticals$180.13M36.38N/AN/A$34.59 per share8.53NBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00TBPHTheravance Biopharma$64.38M8.48N/AN/A$3.57 per share3.06TGTXTG Therapeutics$329M17.08$0.12 per share306.10$1.43 per share24.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/AMDGLMadrigal Pharmaceuticals-$465.89M-$18.05N/AN/AN/A-123.38%-50.54%-37.19%8/6/2025 (Estimated)NBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/ATBPHTheravance Biopharma-$56.42M-$1.18N/A31.20N/A-89.38%-32.37%-16.48%8/4/2025 (Estimated)TGTXTG Therapeutics$23.38M$0.24148.2735.40N/A10.13%18.88%7.05%8/5/2025 (Estimated)Latest MDGL, TBPH, NBRV, TGTX, and ITCI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025TBPHTheravance Biopharma-$0.11-$0.27-$0.16-$0.27$28.08 million$15.39 million5/7/2025Q1 2025TGTXTG Therapeutics$0.19$0.03-$0.16$0.03$117.07 million$120.86 million5/1/2025Q1 2025MDGLMadrigal Pharmaceuticals-$3.62-$3.32+$0.30-$3.32$112.79 million$137.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioITCIIntra-Cellular TherapiesN/A7.667.51MDGLMadrigal Pharmaceuticals0.175.915.58NBRVNabriva Therapeutics0.120.850.52TBPHTheravance BiopharmaN/A4.774.77TGTXTG Therapeutics1.034.023.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipITCIIntra-Cellular Therapies92.33%MDGLMadrigal Pharmaceuticals98.50%NBRVNabriva Therapeutics0.27%TBPHTheravance Biopharma99.10%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipITCIIntra-Cellular Therapies2.60%MDGLMadrigal Pharmaceuticals21.50%NBRVNabriva Therapeutics1.63%TBPHTheravance Biopharma6.90%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableMDGLMadrigal Pharmaceuticals9022.20 million17.43 millionOptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableTBPHTheravance Biopharma35950.00 million46.55 millionOptionableTGTXTG Therapeutics290158.76 million141.86 millionOptionableMDGL, TBPH, NBRV, TGTX, and ITCI HeadlinesRecent News About These CompaniesCramer's Lightning Round: TG Therapeutics is a buyJune 30 at 9:47 PM | nbcnewyork.comNTG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Illinois Municipal Retirement FundJune 30 at 4:11 AM | marketbeat.comTGTX - TG Therapeutics Inc Financials - MorningstarJune 28 at 2:51 PM | morningstar.comMTG Therapeutics: Strong Execution Tempered By An Evolving MarketJune 28 at 7:42 AM | seekingalpha.comSpire Wealth Management Acquires 22,750 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)June 28 at 4:02 AM | marketbeat.comTGTX - TG Therapeutics Inc Valuation - MorningstarJune 27, 2025 | morningstar.comMStocks With Rising Relative Strength: CRISPR TherapeuticsJune 26, 2025 | msn.comTGTX TG Therapeutics, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comTG Therapeutics: Another Possible Avenue Of MS Growth With Azer-CelJune 25, 2025 | seekingalpha.comAssenagon Asset Management S.A. Cuts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)June 20, 2025 | marketbeat.comInsider Selling: Yann Echelard Unloads $369K Of TG Therapeutics StockJune 17, 2025 | benzinga.comAre Options Traders Betting on a Big Move in TG Therapeutics Stock?June 17, 2025 | msn.comYann Echelard Sells 10,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) StockJune 17, 2025 | insidertrades.comInsider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) Director Sells 10,000 Shares of StockJune 16, 2025 | marketbeat.comCantor Fitzgerald Estimates TG Therapeutics FY2026 EarningsJune 10, 2025 | marketbeat.comGAMMA Investing LLC Purchases 176,573 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)June 9, 2025 | marketbeat.comTG Therapeutics (NasdaqCM:TGTX) Stock Rises 13% In Last MonthJune 7, 2025 | uk.finance.yahoo.comTG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 6, 2025 | globenewswire.comWellington Management Group LLP Trims Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)June 6, 2025 | marketbeat.comTwo Sigma Advisers LP Sells 214,800 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)June 6, 2025 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Trading Up 6.2% - Still a Buy?June 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDGL, TBPH, NBRV, TGTX, and ITCI Company DescriptionsIntra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Madrigal Pharmaceuticals NASDAQ:MDGL$295.16 -7.48 (-2.47%) As of 03:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Theravance Biopharma NASDAQ:TBPH$10.92 -0.11 (-0.99%) As of 03:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.TG Therapeutics NASDAQ:TGTX$35.40 -0.60 (-1.65%) As of 03:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
